CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.24) by 58.33 percent. This is a 94.08 percent increase over losses of $(6.42) per share from the same period last year.